2026-11-10 17:54:51 UTC#610427newconfirmednews
Gilead Sciences (GILD) stock news
Gilead Sciences (GILD) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-11-06 17:16:00 UTC#591387newconfirmednews
Gilead's Phase 2 PURPOSE 5 trial shows higher 52-week persistence for twice-yearly lenacapavir vs daily F/TDF
tradingviewimportance 0.50trust 0.70Gilead Sciences, Inc. +0.50Lenacapavir +0.50PURPOSE 5 +0.40+2 entities
2026-11-04 23:05:46 UTC#575894newconfirmednews
Vir Biotechnology secures $90M Gilead deal, extends cash runway to H2 2028 as VIR-5500 and HDV trials advance
quartrimportance 0.50trust 0.70Vir Biotechnology, Inc. +0.50Gilead Sciences, Inc. +0.40VIR-5500 +0.40
2026-11-04 21:53:23 UTC#575502newconfirmednews
Arcus Biosciences Q3 revenue falls on Gilead collaboration wind-down; 2026 revenue guidance set at $70M-$75M
reutersimportance 0.40trust 0.90Arcus Biosciences, Inc. -0.30Gilead Sciences, Inc. -0.20domvanalimab -0.10+1 entities
2026-11-04 21:06:00 UTC#574992newconfirmednews
US markets rally as Dow gains 3% and S&P 500 rises 1.8% following midterm election results
yahooimportance 0.60trust 0.50Amgen Inc. +0.10Gilead Sciences, Inc. +0.10Vertex Pharmaceuticals Incorporated +0.10+2 entities
2026-11-03 19:41:00 UTC#565556newreportednews
Medicaid work requirements threaten $42B in annual drug sales, Health Management Associates report says
dow_jonesimportance 0.60trust 0.70Health Management Associates -0.40Gilead Sciences, Inc. -0.30Novo Nordisk A/S -0.30+2 entities
2026-11-03 18:09:27 UTC#565121newconfirmednews
Dr. Reddy's secures FDA approval for first generic version of Gilead's Yeztugo
seeking alphaimportance 0.50trust 0.70Dr. Reddy's Laboratories Ltd. +0.60Gilead Sciences, Inc. -0.40Yeztugo -0.40+1 entities
2026-11-02 16:46:56 UTC#556782duplicateconfirmednews
Dr. Reddy's receives US FDA tentative approval for generic HIV prevention drug lenacapavir
reutersimportance 0.30trust 0.90Dr. Reddy's Laboratories Ltd. +0.50Gilead Sciences, Inc. +0.30U.S. Food and Drug Administration +0.40+1 entities
2026-11-02 07:37:15 UTC#553370newconfirmednews
Gilead Sciences declares quarterly dividend of $0.82 per share
2026-10-31 02:40:17 UTC#549192newconfirmednews
UBS maintains Gilead Sciences at Buy, raises price target to $195 from $175
2026-10-30 22:40:27 UTC#548747newconfirmednews
JPMorgan maintains Gilead Sciences at Overweight, raises price target to $190 from $170
2026-10-30 19:40:00 UTC#547969newconfirmednews
TD Cowen raises Gilead Sciences price target to $175 from $160
2026-10-30 17:13:00 UTC#547286newconfirmedanalysis
Biopharma stocks including Lilly, Gilead, and J&J reach record highs amid tech sector volatility
marketwatchimportance 0.40trust 0.70Eli Lilly and Company +0.40Gilead Sciences, Inc. +0.40Johnson & Johnson +0.40
2026-10-30 16:56:00 UTC#547209duplicateconfirmednews
Wells Fargo maintains Gilead Sciences at Overweight, raises price target to $190 from $165
2026-10-30 16:47:00 UTC#547136newconfirmednews
Truist Securities maintains Buy rating on Gilead Sciences
2026-10-30 16:45:22 UTC#547156newconfirmednews
Wells Fargo maintains Gilead Sciences at Overweight, raises price target to $190 from $165
2026-10-30 16:20:00 UTC#546968newconfirmednews
Gilead Sciences average analyst price target raised to $171.52, implying 4% upside
2026-10-30 16:14:58 UTC#546915newconfirmednews
RBC Capital maintains Gilead Sciences at Sector Perform, raises price target to $131 from $126
2026-10-30 15:53:45 UTC#547041duplicateconfirmednews
Aspen Neuroscience shares decline 2% in US trading debut following $140.6 million IPO
2026-10-30 04:59:51 UTC#542820duplicateconfirmednews